Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126377 | 0.90 | NR1H4 (0.33) | NR1H4SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL7068659 | 0.79 | NPC1 (0.36) | NR1H4SMN1; SMN2NPC1RAB9AF10 | |
| SCHEMBL7068306 | 0.78 | ACSS2 (0.35) | POLBMAPT | |
| SCHEMBL7071905 | 0.76 | TPSAB1 (0.33) | NR1H4SMN1; SMN2HTTPOLBMEN1 | |
| SCHEMBL7071928 | 0.76 | NPC1 (0.34) | NR1H4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7071924 | 0.76 | NPC1 (0.34) | NR1H4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7073159 | 0.76 | TP53 (0.36) | MAPT | |
| SCHEMBL7068673 | 0.74 | ACSS2 (0.38) | NPC1RAB9AMAPT | |
| SCHEMBL7068661 | 0.73 | NPC1 (0.33) | NR1H4SMN1; SMN2HTTPOLBMEN1 | |
| SCHEMBL7068662 | 0.73 | NPC1 (0.33) | NR1H4SMN1; SMN2HTTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | NR1H4 902/4885SMN1; SMN2 3509/4885HTT 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.